180 Wealth Advisors LLC Buys Shares of 15,000 Edesa Biotech, Inc. (NASDAQ:EDSA)

180 Wealth Advisors LLC bought a new stake in Edesa Biotech, Inc. (NASDAQ:EDSA) in the second quarter, Holdings Channel.com reports. The institutional investor bought 15,000 shares of the company’s stock, valued at approximately $70,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Northern Trust Corp acquired a new stake in Edesa Biotech in the first quarter valued at approximately $83,000. Virtu Financial LLC acquired a new stake in Edesa Biotech in the first quarter valued at approximately $87,000. Geode Capital Management LLC acquired a new stake in shares of Edesa Biotech in the first quarter worth $157,000. Finally, Vanguard Group Inc. lifted its stake in shares of Edesa Biotech by 88.9% in the second quarter. Vanguard Group Inc. now owns 109,158 shares of the company’s stock worth $576,000 after buying an additional 51,369 shares during the last quarter. Hedge funds and other institutional investors own 1.95% of the company’s stock.

Shares of Edesa Biotech stock opened at $8.04 on Thursday. The firm has a fifty day simple moving average of $6.12 and a 200-day simple moving average of $5.78. Edesa Biotech, Inc. has a 1-year low of $4.05 and a 1-year high of $12.00. The stock has a market capitalization of $106.58 million, a price-to-earnings ratio of -7.81 and a beta of 0.71.

Edesa Biotech (NASDAQ:EDSA) last issued its quarterly earnings data on Thursday, August 12th. The company reported ($0.36) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.04). On average, equities research analysts anticipate that Edesa Biotech, Inc. will post -1.18 EPS for the current year.

Edesa Biotech Company Profile

Edesa Biotech, Inc is a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The company product candidate, EB01 is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness.

Featured Story: What is a dead cat bounce?

Want to see what other hedge funds are holding EDSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edesa Biotech, Inc. (NASDAQ:EDSA).

Institutional Ownership by Quarter for Edesa Biotech (NASDAQ:EDSA)

Receive News & Ratings for Edesa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edesa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.